A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis

Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and ach...

Descripción completa

Detalles Bibliográficos
Autores principales: Aouad, Patrick, Yiannikas, Con, Fernando, Suran L, Parratt, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302273/
https://www.ncbi.nlm.nih.gov/pubmed/30622727
http://dx.doi.org/10.1177/2055217318819012
_version_ 1783381949630382080
author Aouad, Patrick
Yiannikas, Con
Fernando, Suran L
Parratt, John
author_facet Aouad, Patrick
Yiannikas, Con
Fernando, Suran L
Parratt, John
author_sort Aouad, Patrick
collection PubMed
description Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and achieved full recovery with oral corticosteroids. This particular form of myositis appears to be unique, and is likely to be a distinct entity from the other four types of immune-mediated myositis.
format Online
Article
Text
id pubmed-6302273
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-63022732019-01-08 A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis Aouad, Patrick Yiannikas, Con Fernando, Suran L Parratt, John Mult Scler J Exp Transl Clin Case Report Alemtuzumab is a high-efficacy disease-modifying therapy for the treatment of relapsing forms of multiple sclerosis and is associated with secondary autoimmune adverse events. We report a novel case of secondary autoimmune myositis that occurred seven months after the initial treatment cycle and achieved full recovery with oral corticosteroids. This particular form of myositis appears to be unique, and is likely to be a distinct entity from the other four types of immune-mediated myositis. SAGE Publications 2018-12-19 /pmc/articles/PMC6302273/ /pubmed/30622727 http://dx.doi.org/10.1177/2055217318819012 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Aouad, Patrick
Yiannikas, Con
Fernando, Suran L
Parratt, John
A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
title A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
title_full A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
title_fullStr A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
title_full_unstemmed A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
title_short A case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
title_sort case of autoimmune myositis after treatment with alemtuzumab for multiple sclerosis
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6302273/
https://www.ncbi.nlm.nih.gov/pubmed/30622727
http://dx.doi.org/10.1177/2055217318819012
work_keys_str_mv AT aouadpatrick acaseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT yiannikascon acaseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT fernandosuranl acaseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT parrattjohn acaseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT aouadpatrick caseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT yiannikascon caseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT fernandosuranl caseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis
AT parrattjohn caseofautoimmunemyositisaftertreatmentwithalemtuzumabformultiplesclerosis

Ejemplares similares